Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Bristol-Myers Squibb Company
EIR
•Bristol-Myers Squibb Company•March 14, 2022

Bristol-Myers Squibb Company – FDA EIR, Mar 14, 2022

Record Details

A routine surveillance Sponsor Inspection of Bristol Myers Squibb (BMS) in Summit, NJ, was conducted by the FDA from March 7 to March 14, 2022. This inspection, requested by the Center for Drug Evaluation and Research (CDER), aimed to assess BMS's compliance with applicable regulations and the Sponsor, Contract Research Organizations and Monitor Compliance Program (CPGM) 7348.810. The review encompassed two clinical studies, including study (b) (4), along with contract agreements, vendor and investigator qualifications, study plans, monitoring reports, and quality assurance activities. A significant point of discussion at the closeout meeting concerned the inconsistent completion of Serious Adverse Event (SAE) forms by clinical sites. Specifically, follow-up SAE forms were sometimes submitted lacking essential details such as the Common Terminology Criteria for Adverse Events (CTCAE) grade or seriousness criteria. This inconsistency potentially impacts the comprehensive evaluation of patient safety events, as the clinical site provides the primary information. Despite this observation, the inspection concluded with a "No Action Indicated (NAI)" classification, indicating no formal inspectional observations (FDA Form 483) were issued. BMS acknowledged the finding, but did not present a detailed plan for corrective actions during the closeout discussion. No samples were collected, and no refusals were encountered.

Company
Bristol-Myers Squibb Company
Inspection date
March 14, 2022
Product type
Biologics
Office
Center for Drug Evaluation and Research
People
  • David Damrau (recipient)
  • Erin Conlin (company_representative)
  • Loreena Sadowski (company_representative)
  • Jacob Muncie (company_representative)
  • Tyanna N. Hadley (investigator)
View Company Profile

ID · d539f239-1103-4fe2-acdf-a6f28938d6e1

Other documents for Bristol-Myers Squibb Company
  • 483 - 2025-07-18July 18, 2025
  • 483 - 2024-12-06December 6, 2024
  • 483 - 2023-06-16June 16, 2023
  • 483 - 2021-02-19February 19, 2021
  • EIR - 2021-02-19February 19, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Bristol-Myers Squibb Company
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.